Despite regular colonoscopy, almost one in 14 participants not taking aspirin in CAPP2 developed colorectal
cancer in less than 5 years, emphasising the need for additional prevention strategies. Our results, taken in
conjunction with recent research, provide a basis for recommendation of aspirin chemoprevention in Lynch
syndrome as standard of care. CAPP3 will seek to establish the optimum dose and duration of aspirin treatment